---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-007054"
form_type: "8-K"
ticker: "KALV"
cik: "0001348911"
company_name: "KalVista Pharmaceuticals, Inc."
filed_at: "2023-03-09T23:59:59+00:00"
generated_at: "2026-06-18T06:43:29.039724+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# KalVista reports Q3 net loss $21.3M; sebetralstat phase 3 enrollment >50%, data H2 2023

## Summary
- Net loss $21.3M ($0.75 per share), no revenue; R&D $20.1M, G&A $6.9M.
- Phase 3 KONFIDENT trial enrollment exceeds 50%; topline data expected H2 2023.
- FDA guidance: no efficacy trials required for ODT sNDA; PMDA guidance for Japan.
- Cash and securities $171.7M; $58M financing extends runway into 2025.
- Phase 2 sebetralstat data published in The Lancet; CFO Palleiko promoted to President.

## SEC filing metadata
- accession: 0000950170-23-007054
- form_type: 8-K
- ticker: KALV
- cik: 0001348911
- company_name: KalVista Pharmaceuticals, Inc.
- filed_at: 2023-03-09T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1348911/000095017023007054/0000950170-23-007054-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1348911/000095017023007054/kalv-20230309.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-007054
- JSON: https://secwatch.observer/filing/0000950170-23-007054.json
- Plain text: https://secwatch.observer/filing/0000950170-23-007054.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.